

REMARKS

Claims 1-48 are hereby canceled to reduce claims fees and without prejudice or disclaimer of any subject matter. The right to file subsequent applications that encompass that matter is reserved.

New claims 49-66 find support throughout the present application including the Drawings and claims as filed originally.

For instance, pg. 19, lines 17-19 discloses the concept of co-administering nucleic acid encoding a mitogen with a vascularization modulating agent. Various mitogens and vascularization modulating agents are specified at pgs. 23-24, bridging paragraph; and pg. 21, lines 13-25, respectively.

Further disclosure relating to the co-administration of a nucleic acid encoding an angiogenic protein into ischemic tissue can be found at pg. 20, lines 5-11. See also pg. 21, last line to pg. 23, line 5; and pg. 23, line 25 to pg. 24, first line.

Ischemic tissue to be treated according to the invention includes heart (myocardial) tissue. See pg. 15, lines 6-10, for instance.

Particular angiogenic proteins for use with the claimed method are disclosed at pg. 20, lines 12-25, for example.

No new matter has been added by virtue of the present amendments.

Early consideration and allowance of the above-captioned application are respectfully requested. The USPTO is authorized to charge our deposit account 04-1104 for any fees needed to consider this submission.

Respectfully submitted,

Date: _____

16 July 2004



Robert L. Buchanan (Reg. 40,927)
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, MA 02205
Tel. (617) 439-4444
Fax (617) 439-4170 / 7748
Customer No.: 21874